Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women

Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vasomotor Symptoms

Age range

20 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy, first-generation (born in Japan, living in the US for less than 5 years)
Japanese female subjects

Treatment and study plan

desvenlafaxine succinate sustained release (DVS SR)

Drug

Primary outcomes

Safety, Tolerability, PK

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

Ascending, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of DVS SR Administered Orally to Healthy Japanese Female Subjects

Important dates

Study start: 2006
Study completion: 2007
First posted: Nov 8, 2006
Registry last updated: Dec 28, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed